Evidence map›Paper›PMID 35446004›Full record

ArticleMycotoxin research2022

Biomonitoring of ochratoxin A, 2'R-ochratoxin A and citrinin in human blood serum from Switzerland.

Alexandra Jaus, Peter Rhyn, Max Haldimann, Beat J Brüschweiler, Céline Fragnière Rime, Judith Jenny-Burri, Otmar Zoller

Open access · hybridAbstract read
In one paragraph

Article in Mycotoxin research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alexandra JausRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland. alexandra.jaus@blv.admin.ch.ORCID http://orcid.org/0000-0001-7193-2938
Peter RhynRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.
Max HaldimannRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.ORCID http://orcid.org/0000-0001-5029-5562
Beat J BrüschweilerRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.ORCID http://orcid.org/0000-0002-7837-5721
Céline Fragnière RimeRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.
Judith Jenny-BurriRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.ORCID http://orcid.org/0000-0003-1503-6666
Otmar ZollerRisk Assessment Division, Federal Food Safety and Veterinary Office (FSVO), Schwarzenburgstrasse 155, 3003, Bern, Switzerland.ORCID http://orcid.org/0000-0003-0956-7604
Federal Food Safety and Veterinary Office · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomonitoring of mycotoxins and their metabolites in biological fluids is increasingly used to assess human exposure. In this study, biomarkers of ochratoxin A (OTA) and citrinin (CIT) exposure were determined in a large number of serum samples from healthy blood donors in Switzerland. In 2019, 700 samples from different regions were obtained. From 240 donors, a second sample (taken 2-9 months later) was available for analysis. Moreover, 355 blood donor samples from 2005 from all regions in Switzerland and 151 additional samples from the southern Swiss region of Ticino from 2005 could be analysed.OTA, 2'R-ochratoxin A (2'R-OTA), ochratoxin alpha (OTα), CIT and dihydrocitrinone (DH-CIT) were analysed using validated targeted methods including precipitation and online SPE clean-up.OTA and 2'R-OTA were frequently detected (OTA in 99%; 2'R-OTA in 51% of the tested samples). The mean concentration in all positive samples was 0.4 ng/mL for OTA and 0.2 ng/mL for 2'R-OTA. OTα was not detected in any sample above the limit of quantification (LOQ). In contrast to OTA, CIT and DH-CIT were only quantifiable in 2% and 0.1% of the samples, respectively. No significant trend was observed between the samples from 2005 and the more recent samples, but OTA concentrations were usually higher in serum samples from the southern Swiss region of Ticino and in males compared to females.Our extensive data fit well within the framework of previously published values for the healthy adult European population.

Indexed as

CitrininOchratoxinsAdultBiological MonitoringFemaleHumansMaleSerumSwitzerlandCitrininochratoxin AOchratoxins2′R-Ochratoxin ACitrininDihydrocitrinoneHuman serumOchratoxin AOchratoxin alpha

Identifiers

PMID35446004
PMCPMC9038883
OpenAlexW4224254351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.